Including a Special Section on Public-Private Partnerships in Global Health Commentary Vol.17 No. 3 (2011) Regional biotechnology – The EU biocluster study Bernhard Zechendorf   Article Vol.17 No. 3 (2011) Analyzing United States Prescribing Information to gain insight into FDA-sponsor discussions Iraj Daizadeh The United States Prescribing Information (USPI) is a key vehicle for communicating the benefit-risk information of a Food and Drug Administration (FDA) approved prescr Article Vol.17 No. 3 (2011) Public–private partnerships in global health Bryan A Liang This issue of the Journal of Commercial Biotechnology includes the papers from the seventh Annual San Diego Health Policy Conference, ‘Public–Private P Article Vol.17 No. 3 (2011) New approaches to global health governance: The evolution to public–private partnerships James Balcius Global health issues that transcend geopolitical borders are altering the nature of global health governance. Sovereign nations are more connected than ever and increas Article Vol.17 No. 3 (2011) Public–private partnerships in trust-based public health social networking: Connecting organizations for regional disease surveillance (CORDS) Louise S Greshama We describe a new trust-based global health security initiative known as CORDS: Connecting Organizations for Regional Disease Surveillance. Initiated and managed by the Article Vol.17 No. 3 (2011) Global governance: Promoting biodiversity and protecting indigenous communities against biopiracy Bryan A Liang Many potentially useful medicines arise from developing countries’ biodiverse environments as well as from indigenous community knowledge. This bioprospecting ha Article Vol.17 No. 3 (2011) Enforcement efforts and partnership with industry: A needed strategy addressing counterfeit drugs Thomas T Kubic Despite some law enforcement successes, organizations engaged in counterfeiting continued manufacturing, distributing and selling a wide range of unsafe medicines durin Article Vol.17 No. 3 (2011) Public–private partnerships in addressing counterfeit medicines: The development of the Partnership for Safe Medicines and the Partnership for Safe Medicines-India Scott LaGanga The global drug supply chain has resulted in tremendous vulnerabilities. Despite individual country efforts, both developed and resource-poor countries have experienced Article Vol.17 No. 3 (2011) Promoting online drug safety: Using public–private partnerships to deter illicit online drug sales Timothy K Mackey Illicit online pharmacies selling counterfeit drugs in a global virtual marketplace remain a critical problem in global health. Yet they continue to operate with little Legal and Regulatory Updates Vol.17 No. 3 (2011) Recapping Section 48D (qualifying therapeutic discovery project credit) − Will it be extended? Peter Wynacht   Legal and Regulatory Updates Vol.17 No. 3 (2011) Trade secrets: At the crossroads of intellectual property and labor and employment law Roy Salins   Legal and Regulatory Updates Vol.17 No. 3 (2011) Notes from the EU Gerry Kamstra  Â